TABLE 4.
Differences in induction and maintenance of immunosuppressive therapy from the comparison at T1 and T12 of KTRs who developed cancer (CA+) and KTRs without cancer diagnosis (CA-).
| Drugs | CA- (n = 753) | CA+ (n = 177) | |
|---|---|---|---|
| Induction of immunosuppression | |||
| Basiliximab - % ATG - % ATG dose - mg/kg | 522 (56.3%) 186 (20%) 4.92 ± 1.1 |
142 (15.3%) 29 (3.1%) 4.44 ± 1.2 |
|
| 2016–2021 interval Basiliximab - % ATG - % ATG dose - mg/kg |
148 (41.7%) 155 (43.6%) 4.8 ± 0.7 |
8 (2.2%) 17 (4.7%) 4.66 ± 0.7 |
|
| Maintenance of immunosuppression | |||
| Ciclosporin - % Tacrolimus - % No - % |
T1 | 41 (4.8%) 635 (74.4%) 1 (0.1%) |
24 (2.8%) 151 (17.7%) 2 (0.2%) |
| Ciclosporin - % Tacrolimus - % No - % |
T12 | 46 (5.7%) 579 (71.8%) 9 (1.1%) |
19 (2.4%) 145 (18%) 8 (1%) |
| MMF-MPA - % | T1 T12 |
645 (75.5%) 579 (71.8%) |
164 (19.2%) 156 (19.4%) |
| mTORi - % | T1 T12 |
17 (2%) 34 (4.2%) |
5 (0.6%) 13 (1.6%) |
| Cumulative steroid dose - mg | T1 T12 |
1109 ± 422 2941 ± 983 |
1040 ± 492 2817 ± 1076 |
ATG, antithymocyte polyclonal immunoglobulins; MMF-MPA, mycophenolate-mycophenolic acid; mTORi, inhibitors of the mTOR system.